Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Negative earnings, no valuation support
Negative FCF, no valuation support
2–5% CAGR, growing but slowly
FCF negative, burning cash after capex
Business Quality & Capital Allocation
Heavy dilution above 5%
Expanded 3+pp, strong improvement
Net cash position, no leverage concern
Below 8%, may not cover cost of capital
Sight Sciences (SGHT) quality: score, margins and returns
Sight Sciences (SGHT) scores 33/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 6 metrics each scored 0 to 100, on -33.4% operating margins and -21.3% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Sight Sciences (SGHT) a high-quality business?+
Sight Sciences scores 33 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -33.4% operating margin and a -21.3% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does Sight Sciences's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from SGHT's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Sight Sciences scores well and where it falls behind.
What is Sight Sciences's return on invested capital (ROIC)?+
Sight Sciences earns about -21.3% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to SGHT's margins and growth on this scorecard to judge durability.
How profitable is Sight Sciences?+
Sight Sciences runs an operating margin of about -33.4% and a net margin of about -35.7%. Revenue has grown at roughly 22.9% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.
SourceQuality score computed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 18 Sept 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.
Peers
Surgical & Medical Instruments & Apparatus · Pick stocks to compare with SGHT
Held by ETFs
SGHT is in 5 US ETFs. The largest of them, with SGHT's weight in each:
Spot a number that looks wrong? Check it in SGHT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing SGHT
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.